Humanized Monoclonal Antibodies

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

Also Known As:

Networked: 217 relevant articles (23 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chang, Chien-Hsing: 3 articles (10/2010 - 05/2005)
2.	Goldenberg, David M: 3 articles (10/2010 - 05/2005)
3.	Choi, So-Young: 2 articles (03/2022 - 08/2019)
4.	Park, Sora: 2 articles (03/2022 - 08/2019)
5.	Calzetta, Luigino: 2 articles (09/2021 - 09/2017)
6.	Rogliani, Paola: 2 articles (09/2021 - 04/2018)
7.	Lanari, Marcello: 2 articles (11/2020 - 01/2013)
8.	Vandini, Silvia: 2 articles (11/2020 - 01/2013)
9.	Cazzola, Mario: 2 articles (04/2018 - 09/2017)
10.	Matera, Maria Gabriella: 2 articles (04/2018 - 09/2017)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2018 - "Humanized monoclonal antibodies that interrupt the PD-L1/PD-1 interaction have shown therapeutic efficacy in patients with advanced urothelial cancer. " 01/01/2016 - "The understanding of the immune responses and their regulation at the intracellular level and the development of fully humanized monoclonal antibodies are the pillars of an approach that could elicit durable clinical responses and even remission in some patients with cancer. " 12/01/2012 - "Currently, humanized monoclonal antibodies against PlGF are studied in early phase clinical trials because PlGF inhibition blocked murine tumor growth and angiogenesis. " 07/01/2003 - "Further studies are needed to assess the role of this oncogene in SSs and to evaluate the application of inhibitory humanized monoclonal antibodies in the treatment regimens for this malignancy." 08/10/2022 - "The idea behind the use of humanized monoclonal antibodies, as inhibitors of immunosuppressive checkpoints used by the tumor to escape from immune system control, is to reduce immunotolerance and direct an intensified anti-tumor immune response. "
2.	Lymphoma (Lymphomas) 03/01/2003 - "Humanized monoclonal antibodies have transformed the treatment of patients with lymphomas. " 10/15/2008 - "Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics." 05/01/2002 - "Humanized monoclonal antibodies are dramatically improving the therapy of lymphomas. " 10/01/1995 - "However, the technique of humanized antibodies has been established and in U.S.A., 131I-labeled antibodies are reported to be effective for the treatment of malignant lymphoma. " 12/01/2005 - "Since 1997, nine humanized antibodies received the approval of the FDA to be used as drugs for the treatment of various diseases including transplant rejections, metastatic breast and colon cancers, leukaemia, non-Hodgkin lymphomas, allergic conditions or multiple sclerosis. "
3.	Asthma (Bronchial Asthma) 01/01/2013 - "New treatment approaches developed to manage some of the phenotypes of severe refractory asthma have included humanized monoclonal antibodies (hMabs). " 08/01/2012 - "The importance of those endotypes has been confirmed by innovative studies using humanized antibodies applied to nasal polyp disease, and by their predictive value for asthma comorbidity. " 01/01/2020 - "Anaphylaxis to three humanized antibodies for severe asthma: a case study." 01/01/2016 - "The connection between eosinophils and asthma development has led to a new class of asthma therapeutics based on blocking eosinophils with humanized antibodies that neutralize IL-5, a potent eosinophil growth, activation, and survival factor. " 04/01/2018 - "Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab."
4.	Breast Neoplasms (Breast Cancer) 07/01/2006 - "Here, an overview of humanized antibodies in human breast cancer is provided, with emphasis on the recent advances and future prospects in treating malignant breast cancer." 07/01/2006 - "In the treatment of breast cancer, humanized antibodies have become a major option. " 07/01/2006 - "Potential use of humanized antibodies in the treatment of breast cancer." 06/01/2006 - "It is a target for therapy; humanized monoclonal antibodies to HER2 have led to increased survival of patients with HER2/neu-positive breast cancer. " 01/01/2018 - "Fully humanized monoclonal antibodies have revolutionized the treatment of many solid tumors, including ovarian, lung, colorectal, and breast cancer. "
5.	Prostatic Neoplasms (Prostate Cancer) 04/01/2005 - "Humanized monoclonal antibodies and small molecules designed to inhibit oncogenic signalling pathways have been subjected to clinical trials in prostate cancer with limited success. " 05/01/2008 - "These results indicate that humanized monoclonal antibodies, conserving the paratope of KM1334, are a promising candidate for therapy of FGF8b-expressing clinical prostate cancers. " 10/01/2006 - "Since fully humanized antibodies targeting the IGF-IR are now in clinical trials, the current review is intended to reveal the mechanisms of potential therapeutic effects of these antibodies on AI prostate cancers." 01/01/2017 - "B7-H3 protein expression correlates with prostate cancer outcomes, and humanized monoclonal antibodies (that is, enoblituzumab) are currently being investigated for therapeutic use. " 12/01/2000 - "This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Administration approval of radioimmunoconjugates for use in diagnosis and staging in colorectal, ovarian, and prostate cancer, from studies demonstrating durable response rates in lymphoma and breast cancer, and from trials demonstrating marked efficacy of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma. "

Related Drugs and Biologics

1.	Antibodies
2.	anti-IgE antibodies
3.	Antigens
4.	Cytokines
5.	Interleukin-6 Receptors (Interleukin 6 Receptor)
6.	Rituximab (Mabthera)
7.	Immunoconjugates (Immunoconjugate)
8.	tocilizumab (atlizumab)
9.	Hemagglutinins (Hemagglutinin)
10.	Vaccines

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Precision Medicine
5.	Combination Drug Therapy (Combination Chemotherapy)